These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11579617)

  • 21. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary hypogonadism in hemochromatosis.
    Meyer WR; Hutchinson-Williams KA; Jones EE; DeCherney AH
    Fertil Steril; 1990 Oct; 54(4):740-2. PubMed ID: 2209900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 24. Transfusional hemochromatosis of the choroid plexus in beta-thalassemia major.
    Duprez T; Maiter D; Cosnard G
    J Comput Assist Tomogr; 2001; 25(3):487-8. PubMed ID: 11351203
    [No Abstract]   [Full Text] [Related]  

  • 25. A case of GH deficiency and beta-thalassemia.
    Smacchia MP; Mercuri V; Antonetti L; Bassotti G; D'Amico T; Pietrobono D; Gargiulo P
    Minerva Endocrinol; 2012 Jun; 37(2):201-9. PubMed ID: 22691893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major.
    Moayeri H; Oloomi Z
    Arch Iran Med; 2006 Oct; 9(4):329-34. PubMed ID: 17061604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type 3 hemochromatosis and beta-thalassemia trait.
    Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
    Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of patients with Cooley's anemia: transfusions and splenectomy.
    Piomelli S
    Semin Hematol; 1995 Oct; 32(4):262-8. PubMed ID: 8560283
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypogonadism and sexual dysfunction in hemochromatosis: the effects of cirrhosis and diabetes.
    Cundy T; Bomford A; Butler J; Wheeler M; Williams R
    J Clin Endocrinol Metab; 1989 Jul; 69(1):110-6. PubMed ID: 2732293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors associated with hypogonadism in β-thalassemia major patients: predictors for a frequent complication of a rare disease.
    Albu A; Barbu CG; Antonie L; Vladareanu F; Fica S
    Postgrad Med; 2014 Sep; 126(5):121-7. PubMed ID: 25295656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gonadotropin replacement in male thalassemia major patients with arrested puberty and acquired hypogonadotropic hypogonadism (AAH): preliminary results and potential factors affecting induction of spermatogenesis.
    De Sanctis V; Soliman AT; Canatan D; Di Maio S; Elsedfy H; Baioumi A; Kattamis C
    Endocrine; 2019 Jan; 63(1):167-170. PubMed ID: 30298384
    [No Abstract]   [Full Text] [Related]  

  • 35. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hypogonadism in idiopathic hemochromatosis].
    Foscolo G; De Menis E; Legovini P; Breda F; Monco A; Scaldaferri E; Conte N
    Minerva Endocrinol; 1989; 14(3):159-63. PubMed ID: 2516238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.